Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Drug News & Perspectives
|
September 20, 2007
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
Giovanni Abbadessa, Paraskevi Vogiatzi, Lorenza Rimassa, et al.
Cancer Biology & Therapy
|
September 14, 2006
The limitless role of p53 in cell cycle machinery: good news or bad news?
Paraskevi Vogiatzi, Marco Cassone, Giovanni Abbadessa, et al.
Translational Oncology
|
February 6, 2017
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Rosaria Chilà, Terence Hall G, Giovanni Abbadessa, et al.
Molecular Cancer Therapeutics
|
October 27, 2011
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown
Sara Previdi, Giovanni Abbadessa, Francesca Dalò, et al.
Plos One
|
November 22, 2013
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model
Sara Previdi, Federica Scolari, Rosaria Chilà, et al.
Plos One
|
June 6, 2017
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
Jianxun Wang, Vasanth Chandrasekhar, Giovanni Abbadessa, et al.
World Journal of Gastroenterology
|
June 3, 2011
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib
Giovanni Abbadessa, Lorenza Rimassa, Tiziana Pressiani, et al.
Anti-Cancer Drugs
|
February 28, 2017
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
Yi Yu, Terence Hall, Sudharshan Eathiraj, et al.
Tumori
|
October 14, 2006
Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin
Lorenza Rimassa, Giuseppe Gullo, Carlo Carnaghi, et al.
Plos One
|
October 16, 2015
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu, Ronald E Savage, Sudharshan Eathiraj, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Drug News & Perspectives
|
September 20, 2007
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
Giovanni Abbadessa, Paraskevi Vogiatzi, Lorenza Rimassa, et al.
Cancer Biology & Therapy
|
September 14, 2006
The limitless role of p53 in cell cycle machinery: good news or bad news?
Paraskevi Vogiatzi, Marco Cassone, Giovanni Abbadessa, et al.
Translational Oncology
|
February 6, 2017
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Rosaria Chilà, Terence Hall G, Giovanni Abbadessa, et al.
Molecular Cancer Therapeutics
|
October 27, 2011
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown
Sara Previdi, Giovanni Abbadessa, Francesca Dalò, et al.
Plos One
|
November 22, 2013
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model
Sara Previdi, Federica Scolari, Rosaria Chilà, et al.
Plos One
|
June 6, 2017
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
Jianxun Wang, Vasanth Chandrasekhar, Giovanni Abbadessa, et al.
World Journal of Gastroenterology
|
June 3, 2011
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib
Giovanni Abbadessa, Lorenza Rimassa, Tiziana Pressiani, et al.
Anti-Cancer Drugs
|
February 28, 2017
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
Yi Yu, Terence Hall, Sudharshan Eathiraj, et al.
Tumori
|
October 14, 2006
Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin
Lorenza Rimassa, Giuseppe Gullo, Carlo Carnaghi, et al.
Plos One
|
October 16, 2015
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu, Ronald E Savage, Sudharshan Eathiraj, et al.
Page
of 5